Articles

Poll

Podcasts

Slideshows

Videos

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Barratt reflects on recent therapeutic developments in IgAN, the most recent being the full FDA approval of sparsentan (Filspari), and the importance of preventing kidney failure.

Jonathan Barratt, PhD, FRCP: Sparsentan Full FDA Approval, Future IgAN Developments

The FDA has granted full approval to sparsentan (Filspari) for slowing kidney function decline in adults with IgAN at risk of disease progression based on PROTECT trial data.

FDA Approves Travere Therapeutics’ Sparsentan to Slow Kidney Function Decline in Adult Primary IgAN

The August 2024 month in review highlights our coverage of pipeline news, a cross-specialty feature about dialysis, and other recent renal news and research from the past few weeks.

Nephrology Month in Review: August 2024

Rizk discusses the recent FDA accelerated approval of iptacopan (Fabhalta) and reflects on the significance of other therapeutic developments in IgAN. 

Dana Rizk, MD: “Very Exciting” Pipeline Developments in IgA Nephropathy

The majority of highly suspected COVID-19 vaccine-associated glomerular disease cases were diagnosed as immunoglobulin A nephropathy and eventually improved with treatment.

IgA Nephropathy Among Most Common COVID-19 Vaccine-Associated Glomerular Diseases

Results suggest the potential utility of several nutritional indexes for reflecting IgAN severity and predicting end-stage renal disease risk.

Nutritional Scores May Aid ESRD Risk Stratification in IgA Nephropathy

Findings from the bidirectional 2-sample Mendelian randomization study suggest a strong positive causal association between atopic dermatitis and IgAN.

Atopic Dermatitis Linked to Increased Risk of IgA Nephropathy

Findings suggest increased intensity of IgM deposits in patients with positive IgM deposition may contribute to adverse clinicopathologic presentation and clinical outcomes. 

Glomerular IgM Deposit Intensity Shows Clinical Significance in IgA Nephropathy

The updated pediatric IgAN prediction tool allows clinicians to assess risk of disease progression 1-2 years post-biopsy.

New Prediction Tool Projects Pediatric IgA Nephropathy Progression Post-Biopsy

Findings from a prespecified secondary analysis of the reduced-dose cohort of the TESTING trial suggest the efficacy of a lower dose of oral methylprednisolone in IgA nephropathy.

Reduced-Dose Methylprednisolone Improves Kidney Outcomes, Delays Renal Failure in High-Risk IgAN

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.